

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

May 14, 2026

To Whom It May Concern

Company Name:	J-Pharma Co., Ltd.
Name of Representative:	President and CEO Masuhiro Yoshitake
Securities code:	520A Tokyo Stock Exchange Growth Market
Contact:	Director and CFO Yutaka Fujimoto
Inquiries:	TEL: +81-3-6432-4270

Notice Regarding the Recognition of Non-operating Income (Grant Income)

We hereby announce that the Company recognized non-operating income (grant income) in the fourth-quarter accounting period of the fiscal year ended March 31, 2026 (January 1, 2026 to March 31, 2026), as detailed below.

1. Details of Non-operating Income (Grant Income)

The Company has recognized grant income of JPY 605,432 thousand. This is attributable to the Company's selection in June 2024 for the "Strengthening Program for Pharmaceutical Startup Ecosystem" implemented by the Japan Agency for Medical Research and Development (AMED), through which the Company advanced research and development of a novel LAT1 inhibitor for multiple sclerosis until March 24, 2026. JPH034, which is supported under this program, is currently undergoing a Phase 1 clinical trial based on an Investigational New Drug (IND) application submitted to the U.S. Food and Drug Administration (FDA).

In addition, as grant income of JPY 414,602 thousand had been recognized in the cumulative third-quarter period of the fiscal year ended March 31, 2026, total grant income of JPY 1,020,034 thousand has been recognized in the income statement for the full fiscal year ended March 31, 2026.

2. Outlook

For details of the impact on financial performance resulting from the recognition of the above-mentioned non-operating income (grant income), please refer to the "Non-consolidated Financial Results for the Fiscal Year Ended March 31, 2026 (Under Japanese GAAP)" announced today.